Martínez C
Unidad de Trasplante Hematopoyético, Servicio de Hematologia, Instituto de Hematología y Oncología, Hospital Clinic, Universidad de Barcelona, Barcelona, España.
Methods Find Exp Clin Pharmacol. 2010 Dec;32 Suppl A:69-71.
Chronic graft versus host disease (GVHD) is still the main cause of long-term non-neoplastic morbidity and mortality in patients receiving an allogeneic hematopoietic stem cell transplantation. Treatment consists of a combination of corticosteroids and calcineurin inhibitors. There is no standardized therapy for cases in which this treatment fails. Recent experimental studies and clinical trials in humans have yielded promising results for imatinib, an inhibitor of tyrosine kinase enzymes involved in the pathogenesis of fibrosis. This article reviews pathophysiologic aspects of scleroderma in the context of GVHD and systemic sclerosis, the experimental bases for the use of tyrosine kinase inhibitors in these diseases, and the first clinical results.
慢性移植物抗宿主病（GVHD）仍然是接受异基因造血干细胞移植患者长期非肿瘤性发病和死亡的主要原因。治疗包括皮质类固醇和钙调神经磷酸酶抑制剂联合使用。对于这种治疗失败的病例，尚无标准化疗法。最近在人体进行的实验研究和临床试验已使伊马替尼（一种参与纤维化发病机制的酪氨酸激酶酶抑制剂）取得了有前景的结果。本文综述了GVHD和系统性硬化症背景下硬皮病的病理生理方面、在这些疾病中使用酪氨酸激酶抑制剂的实验依据以及首批临床结果。
